Under the MoU, signed with Sinopharm-CNBG VP Jiang Xiuchang and CEO of Sinopharm-CNBG's joint venture in the UAE Peng Xiao, capacity and infrastructure to produce the vaccine will be set up in Hungary in 10 months, at the latest, Menczer said.

He noted that the partners in China and the UAE are continuously examining new mutations of the coronavirus and working to develop the most effective vaccines. That cooperation could give Hungary the chance to get fresh information on new mutations and adjust local production accordingly, rapidly and efficiently, he added.